[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552835":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":28,"locations":37,"responsibleParty":63,"collaborators":67,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":11,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":11,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":11,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NW-301V monotherapy in patients with Solid Tumors with KRAS G12V mutation","EXPERIMENTAL",null,[13],"Drug: NW-301V",{"label":15,"type":10,"description":11,"interventionNames":16},"NW-301D monotherapy in patients with Solid Tumors with KRAS G12D mutation",[17],"Drug: NW-301D",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","NW-301V","TCR-T cell targeting KRAS G12V mutation",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"NW-301D","TCR-T cell targeting KRAS G12D mutation",[15],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Rui Liu","CONTACT","0512-67991566","rui.liu@neowisebio.com",{"name":35,"role":31,"phone":32,"phoneExt":11,"email":36},"Yuhui He","yuhui.he@neowisebio.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"The First Affiliated Hospital of Zhejiang University school of Medicine","RECRUITING","Hangzhou","Zhejiang","China","CN",{"type":46,"coordinates":47},"Point",[48,49],120.16142,30.29365,{"lat":49,"lon":48},[52,56,59,61],{"name":53,"role":31,"phone":54,"phoneExt":11,"email":55},"Yinan Shen, Doctor","13486180288","fysyn@163.com",{"name":57,"role":58,"phone":11,"phoneExt":11,"email":11},"Tingbo Liang, Doctor","PRINCIPAL_INVESTIGATOR",{"name":60,"role":58,"phone":11,"phoneExt":11,"email":11},"Xueli Bai, Doctor",{"name":53,"role":62,"phone":11,"phoneExt":11,"email":11},"SUB_INVESTIGATOR",{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","TingBo Liang","Director",[68],{"name":69,"class":70},"Neowise Biotechnology","INDUSTRY","100552835","phase-1-t-cell-receptor-gene-engineered-t-cell-therapy-targeting-kras-mutations-in-the-treatment-of-subjects-with-advanced-solid-tumor-100552835",false,"NCT06478251","T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor","An Open-Label, Dose-Escalation Phase I Clinical Study of T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor","Key Inclusion Criteria:\n\n* Age between 18-75 years\n* Diagnosis of pathologically or histologically confirmed unresectable or advanced solid tumor, and have no standard treatment options available or unable to tolerate the currently available standard treatments\n* HLA-A\\*11:01positive\n* Tumor has KRAS G12V (NW-301V cohort) or G12D (NW-301D cohort) mutation\n* Adequate organ function prior to apheresis and lymphodepleting chemotherapy\n* ECOG performance status of 0-1\n* At least one tumor lesion measurable according to RECIST 1.1\n\n(Additional protocol-defined Inclusion criteria may apply.)\n\nKey Exclusion Criteria:\n\n* Received the following treatments: Cytotoxic chemotherapy within 2 weeks prior to apheresis and within 1 week prior to lymphodepletion; Treatment with antibodies (including but not limited to those with monoclonal antibodies and immune checkpoint inhibitors) or other biologic therapy within 2 weeks prior to apheresis and within 1 week prior to lymphodepletion; Immunosuppressive agents (e.g., calcineurin inhibitors, methotrexate or other chemotherapeutic agents, mycophenolate mofetil, rapamycin, thalidomide, immunosuppressive antibodies such as anti-TNF, anti-IL-6, or anti-IL-6 receptor) within 2 weeks prior to apheresis and within 1 week prior to lymphodepletion\n* History of allergic reactions to cyclophosphamide, fludarabine, or any other chemical or biological components of the drugs used in this study\n* History of chronic or recurrent severe autoimmune disease, or active immune disease requiring treatment with steroids or other immunosuppressive agents within 1 year prior to enrollment\n* Have symptomic CNS metastases\n* Have leptomeningeal disease or carcinomatous meningitis\n* Have ongoing or active infection\n* Active infections with HIV, HBV, HCV, or syphilis\n* Breastfeeding or pregnant\n\n(Additional protocol-defined Exclusion criteria may apply.)","ALL","18 Years","75 Years",{"count":82,"type":83},9,"ESTIMATED","INTERVENTIONAL",[86],"PHASE1","An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics\u002Fpharmacodynamic (PK\u002FPD) of NW-301V and NW-301D in subjects with advanced solid tumor.",[89],"Tumor, Solid","2025-11-19",{"date":92,"type":93},"2025-11-25","ACTUAL",{"date":95,"type":93},"2024-02-01",{"date":97,"type":83},"2027-06",{"name":65,"class":6},1]